Thalassemia differential diagnosis

Jump to navigation Jump to search

Thalassemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thalassemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thalassemia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thalassemia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thalassemia differential diagnosis

CDC on Thalassemia differential diagnosis

Thalassemia differential diagnosis in the news

Blogs on Thalassemia differential diagnosis

Directions to Hospitals Treating Thalassemia

Risk calculators and risk factors for Thalassemia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Differential Diagnosis

Characteristic/Parameter Etiology Mean corpuscular volume Laboratory abnormalities Physical examination Treatment Other associated abnormalities
Thalassemia
Sickle cell anemia
  • Genetic defect resulting in sickled hemoglobin
  • Point mutation in beta-globin chain, converting glutamic acid to valine
  • Abnormal hemoglobin electrophoresis with elevated HbSS fraction
  • Sickled [red blood cells]] on peripheral blood smear
  • Elevated ferritin (due to frequent transfusions and iron overload)
  • Elevated red blood cell mass
  • Folate supplemention
  • Hydroxyurea (to increase fetal hemoglobin production
  • Oxygen supplemention
  • Transfusion support
  • Iron chelation
  • Gene therapy if available
  • Crizanlizumab (P-selectin inhibitor)
  • Patient education and genetic counseling
Iron deficiency anemia
  • Intravenous or oral iron supplementation
  • Blood transfusions
Hemolytic anemia
Sideroblastic anemia

Or

Anemia of chronic disease
Erythropoietin deficiency
  • Epoetin alfa 50-100 units/kg 3 times weekly
  • Darbepoietin 0.45 mcg/kg weekly or 0.75 mcg/kg every 2 weeks[2]
Vitamin B12 or folate deficiency

References

  1. Gibbons RJ (2012). "α-Thalassemia, mental retardation, and myelodysplastic syndrome". Cold Spring Harb Perspect Med. 2 (10). doi:10.1101/cshperspect.a011759. PMC 3475406. PMID 23028133.
  2. Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J; et al. (2017). "A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes". Leukemia. 31 (9): 1944–1950. doi:10.1038/leu.2017.192. PMC 5596208. PMID 28626220.

Template:WH Template:WS